Nuparp 300mg Tablet

• Ovarian cancer
  
• Fallopian tube cancer
  
• Primary peritoneal cancer
  
• Prostate cancer
  

The human body reacts differently to Nuparp 300mg Tablet. Response or undesired symptoms vary from individual to individual. Usually, they disappear with time as the body adjusts to the medicine; these side effects don't need special medical attention. Whereas if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately.

Some of the common side effects of Palbo 100mg Capsule are mentioned below:

Common

• Rash
  
• Constipation
  
• Decrease in appetite
  
• Diarrhea or indigestion
  
• Nausea or vomiting
  
• Changes in the blood count
  
• Shortness of breath
  
• Tiredness

Serious

• Severe anemia
  
• Hypersensitivity reactions
  
• Sepsis (blood infection)
  
• Pneumonia
  

Take Nuparp 300mg Tablet in exact dose as prescribed by the doctor. The typical dose of this capsule varies with age and overall health factor of the patient. It can be taken with or without food but at a fixed time each day to get better results. It should be swallowed as a whole with water without crushing, chewing, or opening the capsule. Don't miss a dose or overdose the medicine.

Nuparp 300mg Tablet contains Rucaparib as an active ingredient. This anticancer medicine belongs to the class of drugs known as PARP (poly ADP-ribose polymerase) inhibitors. This tablet is an inhibitor of poly Adenosine diphosphate-ribose polymerase enzymes, including PARP-1, PARP-2, and PARP-3, that play a vital role in DNA repair. It works by inhibiting the action of specific enzyme that repairs damaged DNA in the cancer cells, resulting in their death.

• Abida, W., Patnaik, A., Campbell, D., Shapiro, J., Bryce, A. H., McDermott, R., ... & TRITON2 investigators. (2020). Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. Journal of Clinical Oncology, 38(32), 3763-3772 - https://pubmed.ncbi.nlm.nih.gov/32795228/
  
• Fizazi, K., Piulats, J. M., Reaume, M. N., Ostler, P., McDermott, R., Gingerich, J. R., ... & Bryce, A. H. (2023). Rucaparib or physician’s choice in metastatic prostate cancer. New England Journal of Medicine, 388(8), 719-732 - https://pubmed.ncbi.nlm.nih.gov/36795891/
  
• Kerliu, L., Myruski, S., Bhatti, A., Soni, P., Petrosius, P., Pervanas, H. C., & Horton, E. R. (2020). Niraparib for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Annals of Pharmacotherapy, 54(10), 1010-1015 - https://pubmed.ncbi.nlm.nih.gov/32172572/
  
• Swisher, E. M., Kwan, T. T., Oza, A. M., Tinker, A. V., Ray-Coquard, I., Oaknin, A., ... & McNeish, I. A. (2021). Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Nature communications, 12(1), 2487 - https://pubmed.ncbi.nlm.nih.gov/33941784/
  
• Shirley, M. (2019). Rucaparib: a review in ovarian cancer. Targeted Oncology, 14(2), 237-246. - https://pubmed.ncbi.nlm.nih.gov/30830551/